Down syndrome: The brain in trisomic mode

Nature Reviews Neuroscience

Volumn 13, Issue 12, 2012, Pages 844-858

  Dierssen, Mara ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; ACETYLCHOLINE; AMYLOID BETA PROTEIN; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DONEPEZIL; E1A ASSOCIATED P300 PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; LEVODOPA; LITHIUM; MEMANTINE; MOOD STABILIZER; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; NORADRENALIN; NOTCH1 RECEPTOR; PHYSOSTIGMINE; PROTEIN C JUN; PROTEIN FOS; PROTEIN P53; RIVASTIGMINE; SAG 1.1; STAT3 PROTEIN; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; UNINDEXED DRUG; XAMOTEROL;

ACETYLCHOLINE RELEASE; AMYGDALOID NUCLEUS; BACTERIAL ARTIFICIAL CHROMOSOME; BASAL GANGLION; BRAIN FUNCTION; BRAIN SIZE; BRAIN STEM; CELL DIFFERENTIATION; CELL FATE; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CEREBELLUM; CHOLINERGIC NERVE CELL; CHROMOSOME 16; CHROMOSOME 21; COGNITION; DENDRITIC SPINE; DNA SEQUENCE; DOWN SYNDROME; EPIGENETICS; FOREBRAIN; FUNCTIONAL NEUROIMAGING; GENE CONTROL; GENE DELETION; GENE DOSAGE; GENE MAPPING; GENE TRANSLOCATION; GRAY MATTER; HIPPOCAMPAL CA1 REGION; HUMAN; IMPLICIT MEMORY; IN VITRO STUDY; IN VIVO STUDY; INFERIOR TEMPORAL GYRUS; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; LANGUAGE ABILITY; LANGUAGE DEVELOPMENT; LEARNING DISORDER; LONG TERM DEPRESSION; LONG TERM MEMORY; LONG TERM POTENTIATION; MEMORY DISORDER; MENTAL PERFORMANCE; MIDDLE FRONTAL GYRUS; MIDDLE TEMPORAL GYRUS; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; NEUROPSYCHOLOGY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARAHIPPOCAMPAL GYRUS; PARIETAL CORTEX; PATHOPHYSIOLOGY; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROBLEM SOLVING; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; REVIEW; SHORT TERM MEMORY; SINGLE DRUG DOSE; SUBVENTRICULAR ZONE; SUPERIOR TEMPORAL GYRUS; SYNAPSE; TEMPORAL CORTEX; TRACTOGRAPHY; TRISOMY 21; VERBAL MEMORY; VISUAL MEMORY;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; TRISOMY;

EID: 84872017448     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3314     Document Type: Review

References (178)

1. Megarbane, A. et al. The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet. Med. 11, 611-616 (2009).
2. Lott, I. T. & Dierssen, M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 9, 623-633 (2010).
3. Khoshnood, B., Greenlees, R., Loane, M. & Dolk, H. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Birth Defects Res. A Clin. Mol. Teratol. 91, S16-S22 (2011).
4. Parker, S. E. et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res. A Clin. Mol. Teratol. 88, 1008-1016 (2010).
5. Hattori, M. et al. The DNA sequence of human chromosome 21. Nature 405, 311-319 (2000).
6. Lott, I. T. Neurological phenotypes for Down syndrome across the life span. Prog. Brain Res. 197, 101-121 (2012).
7. Vicari, S., Bellucci, S. & Carlesimo, G. A. Visual and spatial long-term memory: differential pattern of impairments in Williams and Down syndromes. Dev. Med. Child Neurol. 47, 305-311 (2005).
8. Conners, F. A., Moore, M. S., Loveall, S. J. & Merrill, E. C. Memory profiles of Down, Williams, and fragile X syndromes: implications for reading development. J. Dev. Behav. Pediatr. 32, 405-417 (2011).
9. Edgin, J. O., Pennington, B. F. & Mervis, C. B. Neuropsychological components of intellectual disability: the contributions of immediate, working, and associative memory. J. Intellect. Disabil. Res. 54, 406-417 (2010).
10. Baddeley, A. & Jarrold, C. Working memory and Down syndrome. J. Intellect. Disabil. Res. 51, 925-931 (2007).
11. Lanfranchi, S., Baddeley, A., Gathercole, S. & Vianello, R. Working memory in Down syndrome: is there a dual task deficit? J. Intellect. Disabil. Res. 56,157-166 (2011).
12. Dierssen, M., Herault, Y. & Estivill, X. Aneuploidy: from a physiological mechanism of variance to Down syndrome. Physiol. Rev. 89, 887-920 (2009).
13. Chapman, R. S. & Hesketh, L. J. Behavioral phenotype of individuals with Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 6, 84-95 (2000).
14. Laws, G. & Bishop, D. V. A comparison of language abilities in adolescents with Down syndrome and children with specific language impairment. J. Speech Lang. Hear. Res. 46, 1324-1339 (2003).
15. Purser, H. R. M. & Jarrold, C. Impaired verbal short-term memory in Down syndrome reflects a capacity limitation rather than atypically rapid forgetting. J. Exp. Child Psychol. 91, 1-23 (2005).
16. Zimmer, H. D. Visual and spatial working memory: from boxes to networks. Neurosci. Biobehav. Rev. 32, 1373-1395 (2008).
17. Visu-Petra, L., Benga, O., Tincas, I. & Miclea, M. Visual-spatial processing in children and adolescents with Down's syndrome: a computerized assessment of memory skills. J. Intellect. Disabil. Res. 51, 942-952 (2007).
18. Lanfranchi, S., Carretti, B., Spano, G. & Cornoldi, C. A specific deficit in visuospatial simultaneous working memory in Down syndrome. J. Intellect. Disabil. Res. 53, 474-483 (2009).
19. Colom, R., Jung, R. E. & Haier, R. J. General intelligence and memory span: evidence for a common neuroanatomic framework. Cogn. Neuropsychol. 24, 867-878 (2007).
20. Jarrold, C. & Towse, J. N. Individual differences in working memory. Neuroscience 139, 39-50 (2006).
21. Nairne, J. S. Remembering over the short-term: the case against the standard model. Annu. Rev. Psychol. 53, 53-81 (2002).
22. Nash, H. & Heath, J. The role of vocabulary, working memory and inference making ability in reading comprehension in Down syndrome. Res. Dev. Disabil. 32, 1782-1791 (2011).
23. Saito, S., Jarrold, C. & Riby, D. M. Exploring the forgetting mechanisms in working memory: evidence from a reasoning span test. Q. J. Exp. Psychol. 62, 1401-1419 (2009).
24. Lanfranchi, S., Jerman, O., Dal Pont, E., Alberti, A. & Vianello, R. Executive function in adolescents with Down Syndrome. J. Intellect. Disabil. Res. 54, 308-319 (2010).
25. Lemons, C. J. & Fuchs, D. Phonological awareness of children with Down syndrome: its role in learning to read and the effectiveness of related interventions. Res. Dev. Disabil. 31, 316-330 (2010).
26. Jarrold, C., Cocksey, J. & Dockerill, E. Phonological similarity and lexicality effects in children's verbal short-term memory: concerns about the interpretation of probed recall data. Q. J. Exp. Psychol. 61, 324-340 (2008).
27. Fidler, D. J., Most, D. E. & Guiberson, M. M. Neuropsychological correlates of word identification in Down syndrome. Res. Dev. Disabil. 26, 487-501 (2005).
28. Jarrold, C., Baddeley, A. D. & Phillips, C. E. Verbal short-term memory in Down syndrome: a problem of memory, audition, or speech? J. Speech Lang. Hear. Res. 45, 531-544 (2002).
29. Brock, J. & Jarrold, C. Serial order reconstruction in Down syndrome: evidence for a selective deficit in verbal short-term memory. J. Child Psychol. Psychiatry 46, 304-316 (2005).
30. Robertson Ringenbach, S. D., Chua, R., Maraj, B. K., Kao, J. C. & Weeks, D. J. Bimanual coordination dynamics in adults with Down syndrome. Motor Control 6, 388-407 (2002).
31. Robertson, S. D., Van Gemmert, A. W. & Maraj, B. K. Auditory information is beneficial for adults with Down syndrome in a continuous bimanual task. Acta Psychol. 110, 213-229 (2002).
32. Elliott, D., Weeks, D. J. & Gray, S. Manual and oral praxis in adults with Down's syndrome. Neuropsychologia 28, 1307-1315 (1990).
33. Elliott, D. & Weeks, D. J. Cerebral specialization and the control of oral and limb movements for individuals with Down's syndrome. J. Mot Behav. 22, 6-18 (1990).
34. Welsh, T. N. & Elliott, D. Gender differences in a dichotic listening and movement task: lateralization or strategy? Neuropsychologia 39, 25-35 (2001).
35. Brunamonti, E. et al. Cognitive control of movement in Down syndrome. Res. Dev. Disabil. 32, 1792-1797 (2011).
36. Davis, W. E. & Kelso, J. A. Analysis of "invariant characteristics" in the motor control of down's syndrome and normal subjects. J. Mot. Behav. 14, 194-212 (1982).
37. Virji-Babul, N. et al. Altered brain dynamics during voluntary movement in individuals with Down syndrome. Neuroreport 22, 358-364 (2011).
38. Vicari, S., Bellucci, S. & Carlesimo, G. A. Implicit and explicit memory: a functional dissociation in persons with Down syndrome. Neuropsychologia 38, 240-251 (2000).
39. Vakil, E. & Lifshitz-Zehavi, H. Solving the Raven Progressive Matrices by adults with intellectual disability with/without Down syndrome: different cognitive patterns as indicated by eye-movements. Res. Dev. Disabil. 33, 645-654 (2012).
40. Pinter, J. D., Eliez, S., Schmitt, J. E., Capone, G. T. & Reiss, A. L. Neuroanatomy of Down's syndrome: a high-resolution MRI study. Am. J. Psychiatry 158, 1659-1665 (2001).
41. Raz, N. et al. Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 45, 356-366 (1995).
42. Menghini, D., Costanzo, F. & Vicari, S. Relationship between brain and cognitive processes in Down syndrome. Behav. Genet. 41, 381-393 (2011).
43. Jernigan, T. L., Bellugi, U., Sowell, E., Doherty, S. & Hesselink, J. R. Cerebral morphologic distinctions between Williams and Down syndromes. Arch. Neurol. 50, 186-191 (1993).
44. Jarrold, C., Baddeley, A. D. & Phillips, C. Long-term memory for verbal and visual information in Down syndrome and Williams syndrome: performance on the Doors and People test. Cortex 43, 233-247 (2007).
45. Vicari, S., Bellucci, S. & Carlesimo, G. A. Evidence from two genetic syndromes for the independence of spatial and visual working memory. Dev. Med. Child Neurol. 48, 126-131 (2006).
46. Di Filippo, M. et al. Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. Biol. Psychiatry 67, 666-671 (2010).
47. Tomporowski, P. D., Hayden, A. M. & Applegate, B. Effects of background event rate on sustained attention of mentally retarded and nonretarded adults. Am. J. Ment. Retard. 94, 499-508 (1990).
48. Rigoldi, C. et al. Gait analysis and cerebral volumes in Down's syndrome. Funct. Neurol. 24, 147-152 (2009).
49. Jacola, L. M. et al. Functional magnetic resonance imaging of cognitive processing in young adults with Down syndrome. Am. J. Intellect. Dev. Disabil. 116, 344-359 (2011).
50. Colom, R., Karama, S., Jung, R. E. & Haier, R. J. Human intelligence and brain networks. Dialogues Clin. Neurosci. 12, 489-501 (2010).
51. Fabbro, F., Libera, L. & Tavano, A. A callosal transfer deficit in children with developmental language disorder. Neuropsychologia 40, 1541-1546 (2002).
52. Pennington, B. F., Moon, J., Edgin, J., Stedron, J. & Nadel, L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 74, 75-93 (2003).
53. Sturgeon, X. & Gardiner, K. J. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm. Genome 22, 261-271 (2011).
54. Delabar, J. M. et al. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur. J. Hum. Genet. 1, 114-124 (1993).
55. Korenberg, J. R. et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl Acad. Sci. USA 91, 4997-5001 (1994).
56. Korbel, J. O. et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc. Natl Acad. Sci. USA 106, 12031-12036 (2009).
57. Lyle, R. et al. Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur. J. Hum. Genet. 17, 454-466 (2009).
58. Dierssen, M. et al. Functional genomics of Down syndrome: a multidisciplinary approach. J. Neural Transm. Suppl. 61, 131-148 (2001).
59. Pritchard, M., Reeves, R. H., Dierssen, M., Patterson, D. & Gardiner, K. J. Down syndrome and the genes of human chromosome 21: current knowledge and future potentials. Report on the Expert workshop on the biology of chromosome 21 genes: towards gene-phenotype correlations in Down syndrome. Washington D.C., September 28 October 1, 2007. Cytogenet. Genome Res. 121, 67-77 (2008).
60. Pritchard, M. A. & Kola, I. The "gene dosage effect" hypothesis versus the "amplified developmental instability" hypothesis in Down syndrome. J. Neural Transm. Suppl. 57, 293-303 (1999).
61. Wiseman, F. K., Alford, K. A., Tybulewicz, V. L. & Fisher, E. M. Down syndrome-recent progress and future prospects. Hum. Mol. Genet. 18, R75-R83 (2009).
62. Toiber, D. et al. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiol. Dis. 40, 348-359 (2010).
63. Kahlem, P. et al. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res. 14, 1258-1267 (2004).
64. Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595-600 (2006).
65. Vilardell, M. et al. Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 12, 229 (2011).
66. Ferrando-Miguel, R., Cheon, M. S., Yang, J. W. & Lubec, G. Overexpression of transcription factor BACH1 in fetal Down syndrome brain. J. Neural Transm. Suppl. 67, 193-205 (2003).
67. Shim, K. S., Ferrando-Miguel, R. & Lubec, G. Aberrant protein expression of transcription factors BACH1 and ERG, both encoded on chromosome 21, in brains of patients with Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 67, 39-49 (2003).
68. Osato, M. & Ito, Y. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia? Crit. Rev. Eukaryot. Gene Expr. 15, 217-228 (2005).
69. Altafaj, X. et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 10, 1915-1923 (2001).
70. Ahn, K. J. et al. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 22, 463-472 (2006).
71. Ferrer, I. et al. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol. Dis. 20, 392-400 (2005).
72. Fuentes, J. J. et al. A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum. Mol. Genet. 4, 1935-1944 (1995).
73. Shapiro, B. L. Amplified developmental instability in Down's syndrome. Ann. Hum. Genet. 38, 429-437 (1975).
74. Shapiro, B. L. Developmental instability of the cerebellum and its relevance to Down syndrome. J. Neural Transm. Suppl. 61, 11-34 (2001).
75. Olson, L. E. et al. Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev. Dyn. 230, 581-589 (2004).
76. Yu, T. et al. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res. 1366, 162-171 (2010).
77. Kuhn, D. E. et al. Human chromosome derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem. Biophys. Res. Commun. 370, 473-477 (2008).
78. Kuhn, D. E. et al. Chromosome derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J. Biol. Chem. 285, 1529-1543 (2010).
79. Loudin, M. G. et al. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia 25, 1555-1563 (2011).
80. Pletcher, M. T., Wiltshire, T., Cabin, D. E., Villanueva, M. & Reeves, R. H. Use of comparative physical and sequence mapping to annotate mouse chromosome 16 and human chromosome 21. Genomics 74, 45-54 (2001).
81. Davisson, M. T. et al. Segmental trisomy as a mouse model for Down syndrome. Prog. Clin. Biol. Res. 384, 117-133 (1993).
82. Reeves, R. H. et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nature Genet. 11, 177-184 (1995).
83. Dierssen, M. et al. Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. Cereb. Cortex 13, 758-764 (2003).
84. Sago, H. et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl Acad. Sci. USA 95, 6256-6261 (1998).
85. Villar, A. J. et al. Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm. Genome 16, 79-90 (2005).
86. Ishihara, K. et al. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb. Cortex 20, 1131-1143 (2010).
87. Olson, L. E. et al. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum. Mol. Genet. 16, 774-782 (2007).
88. Belichenko, N. P. et al. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 29, 5938-5948 (2009).
89. Olson, L. E., Richtsmeier, J. T., Leszl, J. & Reeves, R. H. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 306, 687-690 (2004).
90. Aldridge, K., Reeves, R. H., Olson, L. E. & Richtsmeier, J. T. Differential effects of trisomy on brain shape and volume in related aneuploid mouse models. Am. J. Med. Genet. A 143A, 1060-1070 (2007).
91. Duchon, A. et al. The telomeric part of the human chromosome 21 from Cstb to Prmt2 is not necessary for the locomotor and short-term memory deficits observed in the Tc1 mouse model of Down syndrome. Behav. Brain Res. 217, 271-281 (2011).
92. O'Doherty, A. et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 2033-2037 (2005).
93. Morice, E. et al. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn. Mem. 15, 492-500 (2008).
94. Galante, M. et al. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum. Mol. Genet. 18, 1449-1463 (2009).
95. Reynolds, T. The triple test as a screening technique for Down syndrome: reliability and relevance. Int. J. Womens Health 2, 83-88 (2010).
96. Li, Z. et al. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum. Mol. Genet. 16, 1359-1366 (2007).
97. Belichenko, P. V., Kleschevnikov, A. M., Salehi, A., Epstein, C. J. & Mobley, W. C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J. Comp. Neurol. 504, 329-345 (2007).
98. Escorihuela, R. M. et al. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 199, 143-146 (1995).
99. Nambu, J. R., Lewis, J. O., Wharton, K. A. Jr & Crews, S. T. The Drosophila single-minded gene encodes a helix-loop-helix protein that acts as a master regulator of CNS midline development. Cell 67, 1157-1167 (1991).
100. Rachidi, M. et al. Spatial and temporal localization during embryonic and fetal human development of the transcription factor SIM2 in brain regions altered in Down syndrome. Int. J. Dev. Neurosci. 23, 475-484 (2005).
101. Chrast, R. et al. Mice trisomic for a bacterial artificial chromosome with the single-minded 2 gene (Sim2) show phenotypes similar to some of those present in the partial trisomy 16 mouse models of Down syndrome. Hum. Mol. Genet. 9, 1853-1864 (2000).
102. Chrast, R. et al. The mouse brain transcriptome by SAGE: differences in gene expression between P30 brains of the partial trisomy 16 mouse model of Down syndrome (Ts65Dn) and normals. Genome Res. 10, 2006-2021 (2000).
103. Harashima, C. et al. Elevated expression of the G protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of a Down syndrome mouse model. Cell. Mol. Neurobiol. 26, 719-734 (2006).
104. Cooper, A. et al. Trisomy of the G protein-coupled K+ channel gene, Kcnj6, affects reward mechanisms, cognitive functions, and synaptic plasticity in mice. Proc. Natl Acad. Sci. USA 109, 2642-2647 (2012).
105. Alves-Sampaio, A., Troca-Marin, J. A. & Montesinos, M. L. NMDA-mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome. J. Neurosci. 30, 13537-13548 (2010).
106. Gotti, S., Caricati, E. & Panzica, G. Alterations of brain circuits in Down syndrome murine models. J. Chem. Neuroanat. 42, 317-326 (2011).
107. Liu, C. et al. Mouse models for down syndrome-associated developmental cognitive disabilities. Dev. Neurosci. 33, 404-413 (2011).
108. Dierssen, M. et al. Murine models for Down syndrome. Physiol. Behav. 73, 859-871 (2001).
109. Dierssen, M. & de Lagran, M. M. DYRK1A (dual-specificity tyrosine-phosphorylated and-regulated kinase 1A): a gene with dosage effect during development and neurogenesis. ScientificWorldJournal 6, 1911-1922 (2006).
110. Smith, D. J., Zhu, Y., Zhang, J., Cheng, J. F. & Rubin, E. M. Construction of a panel of transgenic mice containing a contiguous Mb set of YAC/P1 clones from human chromosome 21q22.2. Genomics 27, 425-434 (1995).
111. Guedj, F. et al. DYRK1A: a master regulatory protein controlling brain growth. Neurobiol. Dis. 46, 190-203 (2012).
112. Smith, D. J. & Rubin, E. M. Functional screening and complex traits: human 21q22.2 sequences affecting learning in mice. Hum. Mol. Genet. 6, 1729-1733 (1997).
113. Kleschevnikov, A. M. et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153-8160 (2004).
114. Yuste, R. Dendritic spines and distributed circuits. Neuron 71, 772-781 (2011).
115. Dierssen, M. & Ramakers, G. J. Dendritic pathology in mental retardation: from molecular genetics to neurobiology. Genes Brain Behav. 5, 48-60 (2006).
116. Galdzicki, Z. & Siarey, R. J. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav. 2, 167-178 (2003).
117. Siarey, R. J., Stoll, J., Rapoport, S. I. & Galdzicki, Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology 36, 1549-1554 (1997).
118. Kurt, M. A., Davies, D. C., Kidd, M., Dierssen, M. & Florez, J. Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res. 858, 191-197 (2000).
119. Pereira, P. L. et al. A new mouse model for the trisomy of the Abcg1?U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum. Mol. Genet. 18, 4756-4769 (2009).
120. Martinez de Lagran, M. et al. Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons. Cereb. Cortex 2 Jan 2012 (doi:10.1093/cercor/bhr362).
121. Kurt, M. A., Kafa, M. I., Dierssen, M. & Davies, D. C. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 1022, 101-109 (2004).
122. Belichenko, P. V. et al. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 512, 453-466 (2009).
123. Siarey, R. J. et al. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 38, 1917-1920 (1999).
124. Popov, V. I., Kleschevnikov, A. M., Klimenko, O. A., Stewart, M. G. & Belichenko, P. V. Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 519, 1338-1354 (2011).
125. Escorihuela, R. M. et al. Early environmental stimulation produces long-lasting changes on β-adrenoceptor transduction system. Neurobiol. Learn. Mem. 64, 49-57 (1995).
126. Coussons-Read, M. E. & Crnic, L. S. Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field. Behav. Genet. 26, 7-13 (1996).
127. Hyde, L. A., Crnic, L. S., Pollock, A. & Bickford, P. C. Motor learning in Ts65Dn mice, a model for Down syndrome. Dev. Psychobiol. 38, 33-45 (2001).
128. Driscoll, L. L. et al. Impaired sustained attention and error-induced stereotypy in the aged Ts65Dn mouse: a mouse model of Down syndrome and Alzheimer's disease. Behav. Neurosci. 118, 1196-1205 (2004).
129. Escorihuela, R. M. et al. Impaired short-and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 247, 171-174 (1998).
130. Martinez-Cue, C. et al. Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 134, 185-200 (2002).
131. Baamonde, C., Martinez-Cue, C., Florez, J. & Dierssen, M. Gprotein-associated signal transduction processes are restored after postweaning environmental enrichment in Ts65Dn, a Down Syndrome mouse model. Dev. Neurosci. 33, 442-450 (2011).
132. Casanova, M. F., Walker, L. C., Whitehouse, P. J. & Price, D. L. Abnormalities of the nucleus basalis in Down's syndrome. Ann. Neurol. 18, 310-313 (1985).
133. Mann, D. M., Yates, P. O. & Hawkes, J. The pathology of the human locus ceruleus. Clin. Neuropathol. 2, 1-7 (1983).
134. Salehi, A. et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 1, 7ra17 (2009).
135. Chang, Q. & Gold, P. E. Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome. Neurobiol. Learn. Mem. 89, 167-177 (2008).
136. Rueda, N., Florez, J. & Martinez-Cue, C. Effects of chronic administration of SGS111 during adulthood and during the pre-and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome. Behav. Brain Res. 188, 355-367 (2008).
137. Holtzman, D. M. et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl Acad. Sci. USA 93, 13333-13338 (1996).
138. Prasher, V. P., Fung, N. & Adams, C. Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome. Int. J. Geriatr. Psychiatry 20, 496-497 (2005).
139. Van der Molen, M. J. et al. Attentional set-shifting in fragile X syndrome. Brain Cogn. 78, 206-217 (2012).
140. Hanson, J. E., Blank, M., Valenzuela, R. A., Garner, C. C. & Madison, D. V. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. J. Physiol. 579, 53-67 (2007).
141. Fagiolini, M. & Hensch, T. K. Inhibitory threshold for critical-period activation in primary visual cortex. Nature 404, 183-186 (2000).
142. Southwell, D. G., Froemke, R. C., Alvarez-Buylla, A., Stryker, M. P. & Gandhi, S. P. Cortical plasticity induced by inhibitory neuron transplantation. Science 327, 1145-1148 (2010).
143. Fernandez, F. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nature Neurosci. 10, 411-413 (2007).
144. Rueda, N., Florez, J. & Martinez-Cue, C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 433, 22-27 (2008).
145. Owens, D. F. & Kriegstein, A. R. Developmental neurotransmitters? Neuron 36, 989-991 (2002).
146. Baroncelli, L. et al. Brain plasticity and disease: a matter of inhibition. Neural Plast. 2011, 286073 (2011).
147. Owens, D. F. & Kriegstein, A. R. Is there more to GABA than synaptic inhibition? Nature Rev. Neurosci. 3, 715-727 (2002).
148. Becker, L., Mito, T., Takashima, S. & Onodera, K. Growth and development of the brain in Down syndrome. Prog. Clin. Biol. Res. 373, 133-152 (1991).
149. Braudeau, J. et al. Specific targeting of the GABAA receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J. Psychopharmacol. 25, 1030-1042 (2011).
150. Costa, A. C., Scott-McKean, J. J. & Stasko, M. R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33, 1624-1632 (2008).
151. Lockrow, J., Boger, H., Bimonte-Nelson, H. & Granholm, A. C. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 221, 610-622 (2011).
152. Rueda, N. et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J. Alzheimers Dis. 21, 277-290 (2010).
153. Marvanova, M. et al. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol. Cell. Neurosci. 18, 247-258 (2001).
154. Westmark, C. J. et al. Reversal of fragile X phenotypes by manipulation of AßPP/Aβ levels in Fmr1KO mice. PLoS ONE 6, e26549 (2011).
155. Lorenzi, H. A. & Reeves, R. H. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res. 1104, 153-159 (2006).
156. Bianchi, P. et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 30, 8769-8779 (2010).
157. Roper, R. J. et al. Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc. Natl Acad. Sci. USA 103, 1452-1456 (2006).
158. Delcroix, J. D. et al. Trafficking the NGF signal: implications for normal and degenerating neurons. Prog. Brain Res. 146, 3-23 (2004).
159. Salehi, A., Faizi, M., Belichenko, P. V. & Mobley, W. C. Using mouse models to explore genotype-phenotype relationship in Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 13, 207-214 (2007).
160. Tejedor, F. J. & Hammerle, B. MNB/DYRK1A as a multiple regulator of neuronal development. FEBS J. 278, 223-235 (2011).
161. Hammerle, B. et al. Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development 138, 2543-2554 (2011).
162. Yabut, O., Domogauer, J. & D'Arcangelo, G. Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J. Neurosci. 30, 4004-4014 (2010).
163. Ortiz-Abalia, J. et al. Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am. J. Hum. Genet. 83, 479-488 (2008).
164. Guedj, F. et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 4, e4606 (2009).
165. Gockler, N. et al. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J. 276, 6324-6337 (2009).
166. Mazur-Kolecka, B. et al. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice. J. Neurosci. Res. 90, 999-1010 (2012).
167. Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925-937 (2003).
168. Netzer, W. J. et al. Lowering β-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS ONE 5, e10943 (2010).
169. Chakrabarti, L. et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nature Neurosci. 13, 927-934 (2010).
170. Haydar, T. F. & Reeves, R. H. Trisomy 21 and early brain development. Trends Neurosci. 35, 81-91 (2012).
171. Edgin, J. O. et al. Development and validation of the Arizona Cognitive Test Battery for Down syndrome. J. Neurodev Disord. 2, 149-164 (2010).
172. Nadel, L. Down's syndrome: a genetic disorder in biobehavioral perspective. Genes Brain Behav. 2, 156-166 (2003).
173. Ponting, C. P. & Belgard, T. G. Transcribed dark matter: meaning or myth? Hum. Mol. Genet. 19, R162-R168 (2010).
174. Elton, T. S., Sansom, S. E. & Martin, M. M. Trisomy21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. RNA Biol. 7, 540-547 (2010).
175. Senti, K. A. & Brennecke, J. The piRNA pathway: a fly's perspective on the guardian of the genome. Trends Genet. 26, 499-509 (2010).
176. Singh Sandhu, K., Li, G., Sung, W. K. & Ruan, Y. Chromatin interaction networks and higher order architectures of eukaryotic genomes. J. Cell. Biochem. 112, 2218-2221 (2011).
177. Reinholdt, L. G. et al. Meiotic behavior of aneuploid chromatin in mouse models of Down syndrome. Chromosoma 118, 723-736 (2009).
178. Cramer, N. & Galdzicki, Z. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Neural Plast. 2012, 101542 (2012).